Program
riliprubart
Also written as “Riliprubart”, “Riliprubart Prefilled Pen (PFP)” and “BIVV020 (SAR445088)”.
In Sanofi's pipeline, C1s mAb
. Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Anemia, Hemolytic, Autoimmune · Purpura, Thrombocytopenic, Idiopathic, led by Sanofi.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 84 open or running | phase 3since Feb 26, 2024 | Jan 29, 2020 | Jul 9, 2027phase 3 · NCT06290141 |
- Named in Sanofi’s own pipeline as
riliprubart
, phase 3, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 29, 2020First study: phase 1 study in Anemia, Hemolytic, AutoimmuneFirst studyNCT04269551 · 12 enrolled · United States, Germany, Italy and more
- Dec 1, 20202 phase 2 studiesNCT04658472, NCT04669600
- Mar 15, 2021Phase 1 study in Anemia, Hemolytic, AutoimmuneNCT04802057 · 9 enrolled · Germany, Italy, Netherlands and more
- Nov 18, 2021Phase 2 study in Transplant RejectionNCT05156710 · 48 enrolled · United States, Canada, France and more
- Feb 26, 20242 phase 3 studies in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06290141, NCT06290128
- Feb 27, 2025Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06859099 · 300 planned · United States, Argentina, Brazil and more
Ahead
- Jul 9, 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06290141
- Oct 3, 2029Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06859099
TargetBeta
“C1s mAb”the company's pipeline, read by Claude · source
Other programs on C1S
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06859099Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more | 3 | By invitation | Oct 3, 2029 | 300 |
| NCT06290141Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Belgium and more | 3 | Recruiting | Jul 9, 2027 | 160 |
| NCT06290128Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Jun 10, 2026 | 109 |
| NCT05156710Transplant Rejection · United States, Canada, France and more | 2 | Active, not recruiting | Oct 21, 2025 | 48 |
| NCT04802057Anemia, Hemolytic, Autoimmune · Germany, Italy, Netherlands and more | 1 | Terminated | Mar 4, 2025 | 9 |
| NCT04669600Purpura, Thrombocytopenic, Idiopathic · United States, Czechia, Germany and more | 2 | Completed | Feb 15, 2022 | 12 |
| NCT04658472Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Canada, China and more | 2 | Completed | Oct 1, 2025 | 98 |
| NCT04269551Anemia, Hemolytic, Autoimmune · United States, Germany, Italy and more | 1 | Completed | Jan 6, 2022 | 12 |
How it is read
Names in the registry
- “riliprubart”, 2 entries
- “Riliprubart”, 2 entries
- “Riliprubart Prefilled Pen (PFP)”, 1 entry
- “BIVV020 (SAR445088)”, 1 entry
- “SAR445088 (IV)”, 1 entry
Conditions, from the studies’ own filings
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 4 studies
- Anemia, Hemolytic, Autoimmune, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.